September 25, 2024 – The 2024 Biomedical Proof-of-Concept Project Roadshow and Proof-of-Concept Platform Promotion Event, which was focused on promoting the National Regional Technology Transfer and Transformation Center for Universities in Suzhou, was successfully held in the Suzhou Industrial Park (SIP) on September 25, 2024. Notable figures in regional science and innovation, Song Suwei and Gu Chengkaiattended the event and delivered speeches outlining strategic plans for industry development aiming to help researchers from the academic research institutes. Song Suwei and Gu Chengkai provided insights into the future direction of the biomedical industry, emphasizing the importance of collaboration and innovation.
Hua Zhongwei, General Manager of the Yangtze River Delta Sci-Tech Essential Factors Exchange, introduced the Proof-of-Concept platform and highlighted its role in facilitating technology incubation and commercialization. Participating project teams were from prestigious research institutions, including Zhejiang University, Peking Union Medical College, and Nanjing Medical University, and presented their proof-of-concept projects.
Changfu Cheng, Ph.D.，founder of X-CUTAG, provided expert comments on two significant projects: "Selective JAK3 Inhibitors for Autoimmune Diseases" by the team from Peking Union Medical College, led by researcher Zhang Tiantai, and "Anti-Parkinson's Disease Drugs" by the team from Nanjing Medical University.
The event fostered collaboration among enterprises, investors, and the institutes of G60 Kechuang Corridor, focusing on advancing biomedical innovation. X-CUTAG is committed to boosting biomedical advancement, in the hope of being a reliable supporter to the researchers looking to bring in biomedical innovations, and the application of cutting-edge scientific achievements.
About X-CUTAG
X-CUTAG is a leading biotechnology company dedicated to the development of innovative drugs using advanced "deuterium +" technology. The company's mission is to enhance the safety, efficacy, and pharmacokinetic properties of new drugs, thereby improving patient care and treatment options.
